AMCP Market Insights: Payer best practices for timely diagnosis and optimal management of idiopathic hypersomnia.

IF 2.9 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Journal of managed care & specialty pharmacy Pub Date : 2025-09-01 DOI:10.18553/jmcp.2025.31.9-a.s1

Bridget Flavin, Denise Wolff, Zachary Contreras, Ryan Haumschild, Diana Kimmel, Michael Kobernick, Farzana Rahman

引用次数: 0

Abstract

Idiopathic hypersomnia (IH) is a chronic, neurologic disorder with a primary symptom of excessive daytime sleepiness. There are challenges to timely, accurate diagnosis of IH and, therefore, to optimal management. To better understand these challenges and identify opportunities, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in April 2024. Key insights from the discussion related to addressing diagnostic challenges in IH, making coverage decisions for medications used in IH, and implementing coverage criteria for medications used in IH. Suggested payer best practices in IH also emerged from the discussion.

查看原文本刊更多论文

AMCP市场洞察：及时诊断和特发性嗜睡症最佳管理的付款人最佳做法。

特发性嗜睡症（IH）是一种慢性神经系统疾病，主要症状是白天嗜睡过度。对IH进行及时、准确的诊断并因此进行最佳管理是一项挑战。为了更好地了解这些挑战并发现机遇，AMCP市场洞察在2024年4月召集了一个由管理式医疗利益相关者组成的专家小组。讨论的主要见解涉及解决IH的诊断挑战，制定IH所用药物的覆盖决策，以及实施IH所用药物的覆盖标准。讨论中还提出了IH中建议的付款人最佳做法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of managed care & specialty pharmacy Health Professions-Pharmacy

CiteScore

3.50

自引率

4.80%

发文量

131

期刊介绍： JMCP welcomes research studies conducted outside of the United States that are relevant to our readership. Our audience is primarily concerned with designing policies of formulary coverage, health benefit design, and pharmaceutical programs that are based on evidence from large populations of people. Studies of pharmacist interventions conducted outside the United States that have already been extensively studied within the United States and studies of small sample sizes in non-managed care environments outside of the United States (e.g., hospitals or community pharmacies) are generally of low interest to our readership. However, studies of health outcomes and costs assessed in large populations that provide evidence for formulary coverage, health benefit design, and pharmaceutical programs are of high interest to JMCP’s readership.